We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosis

News   May 24, 2018 | Original story from University of Texas Health

 
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosis

Working on a promising treatment for facial tumors tied to tuberous sclerosis complex, from the left, are Adelaide Hebert, M.D.; John Slopis, M.D.; Mary Kay Koenig, M.D.; Joshua Samuels, M.D., M.P.H.; and Hope Northrup, M.D. All are from McGovern Medical School at UTHealth in Houston with the exception of Slopis, who is with The University of Texas MD Anderson Cancer Center. Credit: Maricruz Kwon, UTHealth

 
 
 

RELATED ARTICLES

Concern Over Fake ISO 9001 Accreditation of Chinese Companies

News

A study concludes that fake ISO 9001 quality certificates are very widespread across Chinese companies and that the certification processes of the auditing companies lack credibility.

READ MORE

$11M Study to Jumpstart Radiation Exposure Drug Development

News

The U.S. Department of Defense has turned to the University of Nebraska to jumpstart the development of drug therapies to protect military service members from the effects of radiation exposure.

READ MORE

Hindering Melanoma Metastasis with FDA-approved Drug

News

An FDA-approved drug has been identified that, when used with surgery, hampers metastasis in an animal model. Originally developed and approved ~65 years ago to control blood pressure, the medication resperine also prevents what are known as tumor-derived extracellular vesicles from fusing to healthy cells and sharing their cargo of disease-promoting molecules.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE